Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Ly

Brief Summary

This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Adult patients with Relapsed or Refractory (R/R) Lymphomas, Large Granular Lymphocytic Leukemia (LGL-L), T-cell prolymphocytic leukemia (T-PLL), and Solid Tumors. The Phase 1a stage of the study will explore escalating doses of single-agent KT-333. The Phase Ib stage will consist of 4 expansion cohorts to further characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), LGL-L, and solid tumors.

For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.

Website: https://clinicaltrials.gov/study/NCT05225584

Sponsor: Kymera Therapeutics, Inc.

Detailed Description

This is an open-label Phase 1a (dose escalation)/1b (dose expansion) first-in-human study of KT-333 in adult patients. Patients with relapsed/refractory (R/R) lymphomas, LGL-L, T-PLL, and solid tumors will be enrolled in Phase 1a. Phase 1b will consist of separate cohorts of patients with R/R PTCL, CTCL, LGL-L, and solid tumors.

Contacts and Locations

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05225584

Recruiting

Participating Locations:

Memorial Sloan Kettering Cancer Center
New York, NY, United States
Contact
Zachary Epstein-Peterson, MD
646-608-4176
Recruiting
Sidney Kimmel Cancer Center
Philadelphia, PA, United States
Principal Investigator
Pierluigi Porcu, MD
askphase1@jefferson.edu
215-586-0199
Recruiting
Providence, RI, United States
Contact
Andrew Schumacher
aschumacher@lifespan.org
401-444-3234
Recruiting
UT MD Anderson Cancer Center
Houston, TX, United States
Contact
Auris Huen, MD
aohuen@mdanderson.org
713-745-1113
Recruiting
Emily Couric Clinical Cancer Center
Charlottesville, VA, United States
Principal Investigator
Enrica Marchi, MD
Contact
Mark Dewey
uvacancertrials@uvahealth.org
434-243-0425
Recruiting
Seattle Cancer Care Alliance
Seattle, WA, United States
Contact
Stephen Smith, MD
ssmith50@seattlecca.org
206-606-6546
Recruiting
Columbus, OH, United States
Principal Investigator
John Reneau, MD, PhD
Contact
Lily Yang
lily.yang@osumc.edu
614-293-6191
Recruiting
Abramson Cancer Center
Philadelphia, PA, United States
Contact
Heather Yost
yost@pennmedicine.upenn.edu
267-582-3238
Recruiting
Chao Family Comprehensive Cancer Center
Orange, CA, United States
Principal Investigator
Lauren Pinter-Brown, MD
ucstudy@hs.uci.edu
877-827-8839
Recruiting
Henry Ford Hospital
Detroit, MI, United States
Contact
Cesar Figueras, MBA, HRM, BSN,
cfiguer1@hfhs.org
313-556-8731
Recruiting
Hackensack, NJ, United States
Contact
Elizabeth McCarthy, MSN, RN
elizabethl.mccarthy@hmhn.org
412-860-6447
Recruiting